Omada Health vs U S Physical Therapy
OMDA and USPH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OMDA and USPH compare
U S Physical Therapy is the larger company, worth 1.6 times as much as Omada Health ($1.5B against $933M).
Omada Health grew revenue faster over the last twelve months (43.3% versus 10.4% for U S Physical Therapy).
Omada Health keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with 3.6% at U S Physical Therapy.
U S Physical Therapy pays a dividend yielding 1.8%; Omada Health does not pay one.
Omada Health scores higher on the StockData Score (13 against 9 for U S Physical Therapy), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OMDA | USPH |
|---|---|---|
| Size and price | ||
| Market cap | $933M | $1.5B |
| Share price | $15.24 | $100.10 |
| Change, 1 year | −26.2% | 36.6% |
| Change, 5 years | – | 9.9% |
| Beta (5Y) | 2.38 | 0.72 |
| Employees | 916 | 7,294 |
| StockData Score | ||
| Total score | 13 (better) | 9 |
| Valuation score | 1 | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 1 (better) |
| Valuation | ||
| P/S | 2.8× | 1.8× (better) |
| P/B | 3.4× (better) | 3.5× |
| EV/EBITDA | 52.7× | 17.3× (better) |
| P/FCF | 33.1× | 21.6× (better) |
| FCF yield | 3.0% | 4.6% (better) |
| Fair value | $9.26 | $82.03 |
| Margin of safety | −64.5% | −22.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 43.3% (better) | 10.4% |
| Revenue growth, 5Y average | – | 13.0% |
| Net income growth (TTM) | – | −32.5% |
| EPS growth, 5Y average | – | −10.6% |
| Profitability | ||
| Gross margin | 70.7% (better) | 18.8% |
| Operating margin | 2.1% | 9.1% (better) |
| Net margin | 4.2% (better) | 3.6% |
| FCF margin | 8.5% (better) | 8.2% |
| Return on equity | 5.7% | 6.5% (better) |
| Return on invested capital | 28.2% (better) | 9.1% |
| Financial health | ||
| Debt / equity | 0.00 | 0.57 (better) |
| Net debt / EBITDA | – | 2.11 |
| Interest coverage | 22.4× | – |
| Current ratio | 4.18 (better) | 1.42 |
| Altman Z-score | 7.47 (better) | 2.85 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.8% |
| Years of dividend growth | – | 5 |
| Dividend growth, 5Y average | – | 41.3% |
| Shareholder yield | 0.00% | 1.8% (better) |
| Ownership | ||
| Held by institutions | 85.9% | 109% |
| Held by insiders | 5.4% | 2.6% |
| Insider net buying, 12 months | −$14.6M | −$397K (better) |
| Short interest, % of float | 15.8% | 7.8% |
Go deeper
- OMDA stock overview
- OMDA income statement
- OMDA valuation and score
- USPH stock overview
- USPH income statement
- USPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.